{"prompt": "['Trial ID: LP0162-1339', 'Date: 29-Aug-2018', 'Version: 4.0', 'Page 53 of 129', 'applied (i.e., emollients and TCS should not be used on the same areas at the same time of', 'day); on TCS-untreated areas, the emollients may be applied at all times. Subjects must', 'continue their background emollient treatment throughout the trial (including safety', 'follow-up).', '9.4 Concomitant medication and procedures', 'Any medication or vaccine that the subject receives from 3 months prior to screening through', \"safety follow-up (Week 46) must be recorded in the subject's medical record and the eCRF\", 'along with details such as:', 'Reason for use.', 'Dates of administration including start and stop dates.', 'Dosage information including dose and frequency.', 'Similarly, concomitant procedures (including body location, diagnosis, and start and stop', \"date) must also be recorded in the subject's medical record and the eCRF. Note: in this trial,\", 'only surgical procedures will be recorded.', 'Investigators may prescribe concomitant medications or treatments to provide adequate', 'supportive care as deemed necessary, except for medications listed in Section 9.5. The', \"sponsor's medical expert should be contacted if there are any questions regarding concomitant\", 'or prior therapy.', 'Concomitant medication for conditions other than AD may be continued throughout the trial', 'without any change in dosage whenever possible.', 'All subjects will receive a TCS (Europe: Class 3 [potent]; US: Class 4 [mid-strength]) for', 'treatment of their AD from randomisation through the treatment periods (Week 0 to 32) to be', \"used as needed based on the subject's own judgement (see Section 9.1.3.2 for details\", 'regarding dispensing of TCS [NIMP]). Low potency TCS or TCI may be used at the', \"investigator's discretion on areas of the body where use of the supplied TCS is medically\", 'inadvisable such as areas of thin skin (face, skin fold areas, genital areas, etc.) or on areas', 'where continued treatment is considered unsafe. Low potency TCS or TCI must be reported', 'as concomitant medications.', 'TMF-000005673 - Version 4.0']['Trial ID: LP0162-1339', 'Date: 29-Aug-2018', 'Version: 4.0', 'Page 54 of 129', 'In addition, the following concomitant medications related to AD treatment are permitted', 'from screening through safety follow-up (Week 46):', 'Oral antibiotics, antiviral, or antifungal therapy for skin infections as', 'appropriate.', 'Stable doses of an emollient (see Section 9.3; subjects must apply such', 'emollients twice daily [or more, as needed] for at least 14 days before baseline', 'and throughout trial participation).', 'Oral anti-histamines.', '9.5 Prohibited medication and procedures', 'The following medications are prohibited during the trial from randomisation (Week 0)', 'through Week 32:', 'Use of ultraviolet A or B (UVA or UVB), psoralen + UVA (PUVA), other', 'phototherapy, or tanning beds.', 'Three or more bleach baths per week.', 'Any prohibited topical treatments must be recorded as concomitant medication.', 'The following medications are prohibited during the trial from randomisation through safety', 'follow-up (Week 0 to 46):', 'Other topical medications used for the treatment of AD other than the supplied', 'TCS, except lower potency TCS or TCI which may be used at the', \"investigator's discretion on areas of the body where use of the supplied TCS is\", 'not advisable.', 'Investigational agents other than tralokinumab.', 'Immunoglobulin or blood products.', 'Systemic corticosteroids (nasal and inhaled corticosteroids are allowed).', 'Systemic treatment for AD with an immunosuppressive/ immunomodulating', 'agent (e.g., cyclosporine, mycophenolate mofetil, azathioprine, methotrexate,', 'Janus kinase inhibitors, interferon-gamma, dupilumab or other biologics).', 'Allergen immunotherapy.', 'Live (attenuated) vaccine.', 'TMF-000005673 - Version 4.0']\n\n###\n\n", "completion": "END"}